Work

A Novel Peel to Prevent Post‐Inflammatory Hyperpigmentation After CO2 Resurfacing for Acne Scars

Year: 2025
Type: article
Study design: Clinical Trial
Abstract: ABSTRACT Background Atrophic acne scars are a common dermatological concern, often requiring fractional carbon dioxide (CO2) laser resurfacing for effective treatment. However, in darker skin types (Fitzpatrick III–V), the high risk of post‐inflammatory hyperpigmentation (PIH) remains a significant limitation, affecting treatment outcomes. Aims This study evaluates the efficacy of a novel pre‐ and post‐treatment peel in reducing PIH following fractional CO2 laser resurfacing, particularly in higher Fitzpatrick skin types. The primary outcome was the incidence and severity of PIH, while secondary outcomes included healing time and changes in acne scar grading. Method Twenty‐nine patients underwent fractional CO2 laser resurfacing, with the study group (n = 15) receiving adjunctive peeling treatment before and after the procedure. PIH severity was assessed using the Post‐Inflammatory Hyperpigmentation Area and Severity Index (PIHASI) at Week 6. Healing time and changes in acne scar grading (Goodman and Baron scale) were also analyzed. Results The peel‐treated group had a lower median PIHASI score (0.0 [IQR: 0.0–0.2]) than the no‐peel group (0.2 [IQR: 0.2–0.4]) at Week 6. The Mann–Whitney U test showed a statistically significant difference (z = 2.427, p = 0.015, exact p = 0.016). Re‐epithelialization time was comparable (Day 6.4 in peel group vs. Day 6.2 in control group), and no significant difference was observed in acne scar improvement (scar reduction: 1.27 ± 0.59 vs. 1.36 ± 0.63, p = 0.694). No adverse events were reported. Conclusion The novel peel effectively reduces PIH risk following fractional CO2 laser resurfacing without affecting scar outcomes. While it offers a promising approach for Fitzpatrick III–V patients, further studies with larger cohorts are needed to validate its long‐term efficacy.
Language: English
Subfield: Dermatology
Field: Medicine
Open Access status: hybrid
Estimated APC paid: $3,020
OpenAlex ID: W4412756166
FWCI: 4.01
Cites: 40
Cited by: 5
Related to: 10